1. ESSA Pharma re-elected all seven board members during the AGM. 2. Shareholders approved the auditor's re-appointment and executive compensation. 3. David R. Parkinson received 98.83% votes in his favor. 4. The company previously focused on prostate cancer treatments. 5. The meeting occurred on March 5, 2025.
The re-election of board members typically leads to stability but lacks significant news. Historical trends show similar AGMs result in short-term price stability without major shifts.
The impact of board elections typically has a moderate effect on share prices. With no new clinical developments, the limited changes in governance are seen as neutral.
Immediate stability may be realized, but without new developments, long-term prospects remain unclear. The board's stability may not influence future strategic directions.
ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting").
At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin and Sandy Zweifach to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:
| Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
|---|---|---|---|---|
| David R. Parkinson | 9,131,148 | 98.83 % | 108,123 | 1.17 % |
| Richard M. Glickman | 8,823,885 | 95.50 % | 415,386 | 4.50 % |
| Franklin M. Berger | 8,807,588 | 95.33 % | 431,683 | 4.67 % |
| Scott Requadt | 9,130,637 | 98.82 % | 108,634 | 1.18 % |
| Marella Thorell | 9,135,934 | 98.88 % | 103,337 | 1.12 % |
| Alex Martin | 9,132,226 | 98.84 % | 107,045 | 1.16 % |
| Sandy Zweifach | 9,112,900 | 98.63 % | 126,371 | 1.37 % |
At the Meeting, the Shareholders also approved: (i) the re-appointment of Davidson & Company LLP, Chartered Professional Accountants, as auditors of the Company; and (ii) on a non-binding advisory basis, the compensation of the Company's named executive officers.
David Wood
Chief Financial Officer, ESSA Pharma Inc.
T: 778-331-0962
E: info@essapharma.com
ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com.
SOURCE ESSA Pharma Inc